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ABSTRACT: Introduction: Immune markers are
altered in Parkinson’s disease (PD), but relationships
between cerebrospinal fluid (CSF) and plasma cyto-
kines and associations with neurodegeneration-
associated proteins remain unclear.
Methods: CSF and plasma samples and demo-
graphic/clinical measures were obtained from 35 PD
patients. CSF samples were analyzed for cytokines
(together with plasma) and for α-synuclein, amyloid
β(1-42) peptide, total tau, and phospho(Thr231)-tau.
Results: There were no CSF–plasma cytokine correla-
tions. Interleukin (IL)-8 was higher and interferon-γ, IL-
10, and tumor necrosis factor–α were lower in CSF ver-
sus plasma. In CSF, total tau correlated positively with
IL-8 and IL-1β, whereas α-synuclein correlated posi-
tively with amyloid β(1-42) and negatively with semantic
fluency (a known marker of PD dementia risk).
Discussion: CSF and peripheral cytokine profiles in PD
are not closely related. Associations between CSF IL-8
and IL-1β and tau suggest that CSF inflammatory
changes may relate to tau pathology within PD. CSF
α-synuclein/amyloid β may reflect the risk of developing
PD dementia. © 2020 International Parkinson and
Movement Disorder Society
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Parkinson’s disease (PD) is associated with central
and peripheral immune changes.1 However, the rela-
tionships between these changes and central neu-
rodegeneration are unclear. The cerebrospinal fluid
(CSF) is in close contact with the central nervous system
(CNS), and studying CSF immune markers and
neurodegeneration-associated proteins alongside paired
plasma immune markers may provide additional
insights into these relationships in PD.
The key neurodegeneration-associated protein
involved in PD is α-synuclein, with multiple factors lead-
ing to abnormal aggregation and pathology. CSF total
α-synuclein concentration is generally decreased in PD
when compared with controls,2 possibly reflecting intra-
cellular accumulation/aggregation. PD patients with
cognitive impairment and dementia additionally have
decreased CSF amyloid β and increased total tau levels.3
Increased levels of inflammatory cytokines (eg, inter-
leukin [IL]-1β, IL-6, IL-18, and tumor necrosis factor
[TNF]-α) have been detected in PD CSF when com-
pared with controls,4-6 and many studies have reported
elevated levels of inflammatory cytokines in the serum/
plasma of PD patients when compared with controls.7
A more proinflammatory serum cytokine profile has
further been associated with more rapid disease pro-
gression in early PD,8 and although peripheral cytokine
transport across the blood–brain barrier, with media-
tion of microglial activation and neuronal damage,
could impact on the disease course, a consistent rela-
tionship between peripheral and central cytokine levels
has not been demonstrated in PD.
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The relationships between CSF cytokine changes and
neurodegeneration-associated protein levels are largely
unknown. Currently, limited studies have investigated
this in PD,9 and no studies have investigated CSF α-syn-
uclein, amyloid β, total tau, and phospho-tau alongside
CSF cytokines in a single PD cohort.
This study aimed to examine the relationships
between central and peripheral cytokine levels as well
as CSF cytokine and neurodegeneration-associated pro-
tein associations in a well-characterized, moderate-stage
PD cohort, to provide further insight into the drivers of
central immune activation in PD.
Methods
Patient Recruitment
Ethical approval was obtained from the
Cambridgeshire-2 Research Ethics Committee
(08/H0308/331). Patients were recruited from the PD
Research Clinic at the John van Geest Centre for Brain
Repair in Cambridge. Following screening for contraindi-
cations to lumbar puncture, written informed consent was
obtained. Clinical data gathered included demographic,
medical/drug history, Movement Disorder Society–Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS),
Addenbrooke’s Cognitive Examination–Revised (ACE-R),
semantic fluency (predictive of dementia in PD),10 and
Beck Depression Inventory scores.
Sample Collection and Processing
Lumbar punctures were performed in the left lateral
position at the L3/4 or 4/5 space using aseptic tech-
nique, 1% lignocaine as local anaesthetic and a 22G
spinal needle; ~2 to 5 mL of CSF was collected. A sub-
set of patients (n = 22) had concurrent ethylenediamine
tetraacetic acid (EDTA) venous blood sampling.
CSF samples were centrifuged at 3000g for
15 minutes. Supernatant was stored in ~500 uL aliquots
at −80C. Plasma was extracted from blood by centrifu-
gation at 2000 rpm (~670g) for 15 minutes and stored
at −80C.
Cytokine and Protein Analysis
Samples were analyzed using the Meso Scale Diagnos-
tics (Rockville, MD) electrochemiluminescence platform.
Assays were performed in duplicate, at 1:2 dilution, and
according to the manufacturer’s instructions (https://
www.mesoscale.com/): V-PLEX proinflammatory panel-
1 cytokines (interferon [IFN]-γ, IL-1β, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12p70, IL-13, TNF-α) in CSF and plasma,
and α-synuclein, phospho(Thr231)-tau, total tau, and
amyloid β(1-42) in CSF. Plates were read using the Meso
Scale Diagnostics SECTOR Imager. Data were processed
using Meso Scale Diagnostics Discovery Workbench
software.
Statistical Analysis
Data were analyzed using IBM (Armonk, NY) Statis-
tical Package for the Social Sciences (SPSS) version
25 and GraphPad (San Diego, CA) Prism 7. Cytokine
and protein variables within the CSF and plasma with
assay-detected values in >75% of participants were
included in the analysis. Log10 transformation was per-
formed because of the nonparametric distribution of
variables.
Plasma and CSF cytokine profiles were compared
using a repeated-measures analysis of variance and
paired t tests, with Bonferroni correction for multiple
testing as appropriate. Bivariate correlations were
assessed between CSF cytokines and neurodegeneration-
associated proteins and between CSF markers and clini-
cal measures. Variables with uncorrected significant cor-
relations (P < 0.05) were included in linear regression
analyses with adjustments for relevant confounders.
Results
Participant Demographics
Demographic and clinical measures in the PD cohort
(n = 35) were expressed as mean (standard deviation)
or percentage: age 65.4 (7.6) years, sex 48.6% male,
years of education 18.7 (3.9), disease duration 5.4 (5.6)
years, Movement Disorder Society–Unified Parkinson’s
Disease Rating Scale part III (on treatment) 31.0 (12.1),
ACE-R score 90.3 (9.4), Beck Depression Inventory
score 9.1 (7.7), and semantic fluency score 23.9 (8.4).
CSF samples from all patients and paired plasma
samples from 22 patients were available for analysis.
CSF and Plasma Cytokines
The cytokines IFN-γ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-
12p70, and TNF-α in CSF and IFN-γ, IL-6, IL-8, IL-10,
and TNF-α in plasma had measurable values in >75% of
the analyzed samples and were used for further analysis.
Bivariate analysis of the detected cytokines in both
CSF and plasma (IFN-γ, IL-6, IL-8, IL-10, and TNF-α)
indicated no correlations between CSF and plasma
levels in this cohort. Repeated-measures analysis of var-
iance indicated a significant overall difference between
CSF and plasma profiles (F = 32.75, P < 0.001). Paired
comparisons between CSF and plasma values indicated
that IL-8 was significantly higher, whereas IFN-γ, IL-
10, and TNF-α were significantly lower in CSF versus
plasma following Bonferroni correction for multiple
testing (P < 0.005; Fig. 1A).
CSF Cytokines and Neurodegeneration-
Associated Proteins
Both α-synuclein and amyloid β(1-42) were the most
abundant measured neurodegeneration-associated
2 Movement Disorders, 2020
W I J E Y E K O O N E T A L
proteins in CSF, whereas total tau and phospho-tau
were present at low concentrations (Fig. 1B). Bivariate
correlation analyses between all measured CSF
neurodegeneration-associated proteins and CSF cyto-
kines revealed significant relationships between
α-synuclein and amyloid β(1-42) (Pearson’s r = 0.499,
P = 0.004), total tau and IL-1β (Pearson’s r = 0.554,
P = 0.002), total tau and IL-8 (Pearson’s r = 0.591,
P < 0.001), and phospho-tau and IL-2 (Pearson’s
r = −0.667, P = 0.001; Table S1, Fig. 1D–G).
FIG. 1. A: Paired comparisons of analyzed CSF and plasma cytokines in patients with Parkinson’s disease (n = 22). B: Mean levels of CSF neurodegen-
erative proteins in patients with Parkinson’s disease (n = 35). C: Scatter plot of semantic fluency score versus log10CSF α-synuclein. D–G: Graphs dem-
onstrating relationships between CSF markers. CSF, cerebrospinal fluid; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor. [Color figure can be
viewed at wileyonlinelibrary.com]
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Multivariate linear regression analyses with each
neurodegeneration-associated protein as the dependent
variable confirmed significant positive relationships
between tau and IL-8 (β = 0.779, P = 0.001), tau and
IL-1β (β = 0.338, P = 0.041), and α-synuclein and amy-
loid β(1-42) (β = 0.605, P = 0.010), with age included
as covariate (Table 1).
CSF Markers and Clinical Variables
Bivariate correlation analyses revealed a significant
relationship between semantic fluency and α-synuclein
that withstood correction for multiple testing
(r = −0.53, P = 0.003) as well as nominally significant
associations (P < 0.05) between semantic fluency and
IL-6, ACE-R and IL-6, and age and both IFN-γ and IL-
1β (Table S2). There were no associations with mea-
sures of motor severity.
Multivariate linear regression analyses with semantic
fluency and ACE-R score as dependent variables,
including age as covariate, confirmed the significant
relationship between semantic fluency and α-synuclein
(β = −8.82, P = 0.023), but not the associations
between ACE-R and CSF variables (Fig. 1C, Table S3).
Discussion
This study has demonstrated that the cytokine profile
in PD CSF does not relate closely to that seen in the
periphery, suggesting that factors within the CNS may
play a role in influencing local CNS inflammation. In
keeping with this, our data also revealed positive corre-
lations between CSF proinflammatory cytokines (IL-8,
IL-1β) and CSF total tau in PD. In addition, we have
confirmed a positive correlation between CSF
α-synuclein and amyloid β(1-42) and found a negative
correlation between CSF α-synuclein and semantic
fluency—a key clinical predictor of dementia in PD.10
Previous studies investigating relationships between
CSF and serum/plasma cytokines in PD have reported
elevated TNF-α in CSF compared to serum and correla-
tions between CSF and serum levels of IL-6, IL-1β, and
IL-10 in PD and controls.11 The different findings com-
pared with our study may reflect variations in cohort
demographics, disease stage, and methodology. The lack
of CSF–peripheral cytokine correlations in our results
suggests that central and peripheral cytokine levels may
behave independently of each other and that CSF changes
may not simply reflect passive diffusion of circulating
cytokines to the CNS. Contributory factors to CSF cyto-
kine levels may include cytokine production from CNS
cells (eg, microglia, astrocytes, and neurons), peripheral-
derived immune cells trafficking into the CNS, and active
transport across the blood–brain barrier.12 Thus, CSF
cytokines may better reflect CNS pathology, compared to
peripheral cytokines, which may be driven by factors
including peripheral α-synuclein aggregation/pathology,
systemic infections/inflammation, and microbial changes
(eg, gut microbiome),13 with separate relevance to PD
and disease progression.8
Within PD CSF, the proinflammatory cytokines IL-1β
and IL-8 correlated positively with total tau, whereas
the anti-inflammatory IL-2 correlated negatively with
phospho-tau. Potential causal links between tau species
and immune changes are unclear, but inflammation has
been shown to influence tau production/pathology.14
CSF tau/phospho-tau levels have also been linked to
cognitive progression and dementia within PD,3
whereas postmortem and genetic studies have con-
nected increased tau pathology and expression with a
higher risk of PD cognitive dysfunction/dementia.15,16
The current findings linking CSF tau to inflammatory
cytokines in PD may therefore be of some relevance in
TABLE 1. Linear regression analysis, with log10CSF total tau, log10CSF phospho-tau, and log10CSF α-synuclein
as the dependent variables
Variable β Coefficient Significance
95% Confidence Interval for β
Lower Upper
Dependent variable, log10CSF total tau
Age 0.001 0.869 −0.008 0.009
log10CSF IL-1β 0.338 0.041* 0.014 0.661
log10CSF IL-8 0.779 0.001* 0.332 1.225
Dependent variable, log10CSF phospho-tau
Age 0.002 0.874 −0.020 0.024
log10CSF IL-1β −0.499 0.122 −1.150 0.152
log10CSF IL-2 −0.692 0.104 −1.548 0.164
log10CSF TNF-α −0.197 0.606 −1.005 0.610
Dependent variable, log10CSF α-synuclein
Age 0.007 0.455 −0.011 0.024
log10CSF amyloid β(1-42) 0.595 0.011* 0.144 1.046
*P < 0.05. Bold text indicates results relating to variables with statistical significance (P < 0.05).
CSF, cerebrospinal fluid; IL, interleukin; TNF, tumor necrosis factor.
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terms of the biological basis of cognitive heterogeneity
within PD, regardless of findings in healthy controls.
However, control studies will be essential to gain a
more complete understanding of the tau–cytokine rela-
tionships within the CSF.
The positive correlation between CSF α-synuclein and
amyloid β is consistent with previous studies.17 Higher
CSF α-synuclein levels are associated with worse
(lower) semantic fluency, which is predictive of the
development of PD-associated dementia.10 Although
the relationship between CSF α-synuclein and cognitive
function in PD is complex, this result is consistent with
previous studies in similar-stage PD, linking posterior
cortical impairment to increased CSF α-synuclein.18
These observations further support the importance of
α-synuclein in the development of PD dementia, as has
been demonstrated in postmortem studies.15
The limitations of this study include the small sample
size, lack of plasma samples in all subjects, and the
absence of matched healthy control samples. Further-
more, not all cytokines could be adequately measured
in the CSF and plasma using this assay, and higher sen-
sitivity assays may be needed for improved resolution
of the low-level cytokines. However, the assessment of
multiple neurodegeneration-associated proteins and
cytokines in simultaneously obtained CSF and plasma
samples from a clinically well-characterized cohort has
uniquely allowed interrelationships between these fac-
tors to be explored further in PD. Longitudinal assess-
ments of these relationships in larger PD cohorts and
matched healthy controls would now be of interest.
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Data are available upon reasonable request.
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